Abstract Background Research questions To compare the efficacy of nintedanib and
pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of …

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown origin
that usually results in death from secondary respiratory failure within 2–5 years of diagnosis …

The use of exogenous mitochondria to replenish damaged mitochondria has been proposed
as a strategy for the treatment of pulmonary fibrosis. However, the success of this strategy is …

Accumulating evidence indicates that most primary Wharton's jelly mesenchymal stem cells
(WJ-MSCs) therapeutic potential is due to their paracrine activity, ie, their ability to modulate …

Recent advances have uncovered the non-random distribution of 7, 8-dihydro-8-oxoguanine
(8-oxoGua) induced by reactive oxygen species, which is believed to have epigenetic …

Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition characterized by the abnormal
regulation of extracellular matrix (ECM) and epithelial‐mesenchymal transition (EMT). In this …

Background Early appropriate diagnosis and treatment of interstitial lung diseases (ILD) is
crucial to slow disease progression and improve survival. Yet it is unknown whether initial …

Background: Nintedanib is an oral multitarget tyrosine kinase inhibitor approved for the
treatment of patients with idiopathic pulmonary fibrosis (IPF). Recent evidence demonstrated …

Lung fibrosis, including idiopathic pulmonary fibrosis, is an intractable disease accompanied
by an irreversible dysfunction in the respiratory system. Its pathogenesis involves the …

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease caused by an
aberrant repair of injured alveolar epithelial cells. The maintenance of the alveolar …